Fortis Healthcare
- Market Cap
- ₹62,284 Cr
- P/E
- 59.96
Key Fundamentals
MidcapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 13.40%
- Debt to Equity
- 0.30
- EPS (TTM)
- ₹13.76
- Book Value
- ₹138.79
- Market Cap
- ₹62,284 Cr
- P/E (TTM)
- 59.96
- P/B
- 5.94
- ROE
- 11.20%
- Dividend Yield
- 0.12%
- EBITDA
- ₹2,136 Cr
- 52W High
- ₹1,010.10
- 52W Low
- ₹704.95
- Day Range
- ₹802.40 – ₹829.00
- Volume
- 22,88,213
Peer Comparison
Healthcare › Healthcare Services › Hospital
| 9,200.00 | 59.00 | 1,32,282 | 12.47 | 0.23% | 21.50% | 17.40% | 27,630 | 2,337 | |
| 1,081.00 | 76.23 | 1,05,215 | 9.28 | 0.20% | 14.70% | 14.70% | 9,146 | 1,380 | |
| 702.20 | 101.77 | 92,366 | 6.01 | 0.00% | 6.72% | 8.30% | 12,370 | 873 | |
| 779.30 | 110.70 | 67,929 | 8.72 | 0.41% | 11.30% | 11.60% | 6,508 | 564 | |
| 825.00 | 59.96 | 62,284 | 5.94 | 0.13% | 11.20% | 13.40% | 9,910 | 1,061 | |
| 1,480.20 | 64.33 | 39,798 | 9.20 | 0.03% | 15.20% | 17.40% | 5,053 | 613 | |
| 1,943.70 | 46.25 | 39,722 | 7.94 | 0.24% | 20.50% | 15.50% | 10,273 | 859 | |
| Median 7 companies | 1,081.00 | 64.33 | 67,929 | 8.72 | 0.20% | 14.70% | 14.70% | 9,910 | 873 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 47
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 40
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 52
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 34
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 11
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 49
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company has delivered good profit growth of 64.3% CAGR over last 5 years
Weaknesses
2- Stock is trading at 5.94 times its book value
- Company has a low return on equity of 9.87% over last 3 years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 7 | 4 | 8 |
| Oscillators | Bearish | 3 | 4 | 2 |
| Moving Averages | Strong Bullish | 4 | 0 | 6 |
Oscillators
Bearish
Overall
Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 60.58
- Neutral
- MACD (12,26,9)
- 5.62
- Bullish
- SMA (50)
- 798.09
- Bullish
- SMA (200)
- 889.57
- Bearish
As of
Analyst Rating
14 of 17 analysts rate Buy, 3 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +8.07% |
|---|---|
| 5Y | +17.76% |
| 3Y | +13.17% |
| 1Y | +17.28% |
| TTM | +17.51% |
Net profit
| 10Y | +38.16% |
|---|---|
| 5Y | Turned to profit |
| 3Y | +18.90% |
| 1Y | +31.52% |
| TTM | +2.22% |
Operating cash flow
| 10Y | +23.43% |
|---|---|
| 5Y | +26.98% |
| 3Y | +24.88% |
| 1Y | +12.43% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +20.65 pp |
|---|---|
| 5Y | +12.82 pp |
| 3Y | +5.36 pp |
| 1Y | +2.44 pp |
| TTM | +0.16 pp |
Revenue by year
| Mar 2017 | ₹4,574 Cr |
|---|---|
| Mar 2018 | ₹4,561 Cr |
| Mar 2019 | ₹4,469 Cr |
| Mar 2020 | ₹4,632 Cr |
| Mar 2021 | ₹4,030 Cr |
| Mar 2022 | ₹5,718 Cr |
| Mar 2023 | ₹6,298 Cr |
| Mar 2024 | ₹6,893 Cr |
| Mar 2025 | ₹7,783 Cr |
| Mar 2026 | ₹9,128 Cr |
Net profit by year
| Mar 2017 | ₹479 Cr |
|---|---|
| Mar 2018 | −₹934 Cr |
| Mar 2019 | −₹224 Cr |
| Mar 2020 | ₹91.00 Cr |
| Mar 2021 | −₹56.00 Cr |
| Mar 2022 | ₹790 Cr |
| Mar 2023 | ₹633 Cr |
| Mar 2024 | ₹645 Cr |
| Mar 2025 | ₹809 Cr |
| Mar 2026 | ₹1,064 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Fortis Healthcare Ltd trades at ₹806.8 as of 2026-11-17 with a market cap of ₹60,910 Cr. The company has delivered strong 5-year profit CAGR of 64% and 5-year sales CAGR of 18%, but the stock trades at a P/E of 58.63x and 5.81x book value, while return on equity stands at 10.47%. The stock is down roughly 20% from its 52-week high of ₹1,010.1.
- Strong long-term profit compounding: 5-year compounded profit growth of 64%, reflecting a significant improvement in earnings power over the medium term.
- Healthy revenue momentum: TTM sales growth of 18% and 5-year compounded sales growth of 18% indicate sustained top-line expansion.
- Improving return on equity trajectory: ROE has risen from a 10-year average of 5% to 11% in the last year, showing improving capital efficiency.
- Conservative leverage: Debt-to-equity ratio of 0.34 provides financial flexibility and limits balance sheet risk for a capital-intensive hospital business.
- Solid long-term stock performance: 10-year stock CAGR of 18% and 5-year CAGR of 23% demonstrate sustained wealth creation over extended periods.
- Double-digit ROCE: Return on capital employed of 12.13% suggests the company is generating reasonable returns above its cost of debt on deployed capital.
- 10-year compounded sales growth of 8% combined with 10-year compounded profit growth of 60% indicates significant operating leverage and margin expansion over the long term.
- High price-to-book multiple: Trading at 5.81x book value implies a heavy premium to net assets, which could compress if profitability plateaus.
- Slowing profit growth: TTM profit growth has decelerated sharply to 7% compared to the 5-year CAGR of 64%, raising questions about sustainability of high earnings multiples.
- Negligible dividend yield: At 0.12%, the dividend yield offers virtually no income return to shareholders, making the stock entirely dependent on capital appreciation.
- Negative 1-year stock return: The stock has declined 13% over the past year and is trading roughly 20% below its 52-week high of ₹1,010.1, indicating weakening sentiment.
- Moderate ROE relative to valuation: ROE of 10.47% is modest for a stock commanding nearly 59x earnings, suggesting the premium is not fully justified by current profitability.
- 3-year average ROE of approximately 10% remains below levels typically expected for companies trading at such elevated valuation multiples in the healthcare sector.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Fortis Healthcare is executing well on both organic and inorganic fronts, posting 17.3% revenue growth in Q2FY27 while aggressively expanding its Bengaluru cluster through the ₹277 crore Suguna Hospital acquisition. The CGIO departure is a watch item but not a structural concern. No material headwinds are visible in recent news flow, and the trend appears firmly positive with continued capacity expansion likely to support future growth.
- Q2FY27 revenue up 17.3% Nov 5
Consolidated revenue rose 17.3% YoY to ₹2,735 crore in Q2FY27, driven by strong hospital business growth and diagnostics expansion.
- Suguna Hospital acquired for ₹277Cr Oct 28
Fortis acquired Suguna Hospital in Bengaluru for ₹277 crore via subsidiary IHL, adding 110 beds (expandable to 150) and taking Bengaluru capacity to ~1,000 beds. The deal valued at ~5.6x EV/revenue follows the People Tree Hospital purchase in Jan 2026, giving Fortis ~500 potential beds in the north-west Bengaluru corridor.
- CGIO Ritu Garg resigns Oct 31
Chief Growth & Innovation Officer Dr. Ritu Garg resigned effective October 31, 2026, citing a professional opportunity outside the organization.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,770 | 1,680 | 1,786 | 1,859 | 1,988 | 1,928 | 2,007 | 2,167 | 2,331 | 2,265 | 2,365 | 2,545 | 2,735 |
| Expenses | 1,440 | 1,396 | 1,405 | 1,516 | 1,554 | 1,553 | 1,572 | 1,676 | 1,775 | 1,759 | 1,832 | 2,008 | 2,112 |
| Operating Profit | 330 | 284 | 381 | 343 | 435 | 375 | 435 | 491 | 556 | 506 | 532 | 537 | 623 |
| OPM % | 19% | 17% | 21% | 18% | 22% | 19% | 22% | 23% | 24% | 22% | 23% | 21% | 23% |
| Other Income | 18 | 19 | 17 | 13.01 | −42 | 47 | −29 | 31 | 50 | −34 | −2 | 28 | 16 |
| Interest | 32 | 33 | 35 | 35 | 36 | 45 | 68 | 70 | 75 | 86 | 84 | 80 | 78.3 |
| Depreciation | 84 | 87 | 92 | 91 | 95 | 97 | 102 | 101 | 106 | 120 | 122 | 122 | 128 |
| PBT | 231 | 183 | 271 | 229 | 261 | 279 | 237 | 351 | 425 | 266 | 324 | 363 | 432 |
| Tax % | 21% | 27% | 25% | 24% | 26% | 9% | 21% | 24% | 23% | 26% | 16% | 25% | 26% |
| Net Profit | 184 | 134 | 203 | 174 | 193 | 254 | 188 | 267 | 329 | 197 | 271 | 273 | 320 |
| EPS (₹) | 2.30 | 1.78 | 2.37 | 2.20 | 2.34 | 3.28 | 2.44 | 3.45 | 4.26 | 2.57 | 3.52 | 3.53 | 4.14 |
| YoY Sales growth | 10 | 8 | 9 | 12 | 12 | 15 | 12 | 17 | 17 | 17 | 18 | 17 | 17 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,966 | 4,199 | 4,574 | 4,561 | 4,469 | 4,632 | 4,030 | 5,718 | 6,298 | 6,893 | 7,783 | 9,128 | 9,910 |
| Expenses | 3,857 | 4,106 | 4,220 | 4,287 | 4,238 | 4,022 | 3,626 | 4,649 | 5,196 | 5,625 | 6,195 | 7,043 | 7,711 |
| Operating Profit | 109 | 92 | 354 | 274 | 231 | 610 | 404 | 1,069 | 1,101 | 1,268 | 1,588 | 2,085 | 2,198 |
| OPM % | 2.8% | 2.2% | 8% | 6% | 5% | 13% | 10% | 19% | 17% | 18% | 20% | 23% | 22% |
| Other Income | 92 | 299 | 649 | −689 | 228 | 126 | 95 | 367 | 157 | 64 | −11 | 45 | 8 |
| Interest | 152 | 133 | 229 | 258 | 337 | 205 | 166 | 147 | 129 | 131 | 184 | 314 | 329 |
| Depreciation | 235 | 225 | 222 | 239 | 233 | 292 | 291 | 301 | 316 | 342 | 386 | 449 | 492 |
| PBT | −185 | 34 | 552 | −912 | −110 | 239 | 43 | 988 | 814 | 858 | 1,007 | 1,366 | 1,385 |
| Tax % | 2% | −24% | 13% | 2% | 103% | 62% | 230% | 20% | 22% | 25% | 20% | 22% | — |
| Net Profit | −130 | 42 | 479 | −934 | −224 | 91 | −56 | 790 | 633 | 645 | 809 | 1,064 | 1,062 |
| EPS (₹) | −3.10 | 0.40 | 8.14 | −19.46 | −3.96 | 0.77 | −1.45 | 7.35 | 7.80 | 7.93 | 10.26 | 13.80 | 13.76 |
| Div. Payout % | Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number. | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 13% | 13% | 10% | 7% | — |
| Sales growth | 14 | 6 | 9 | 0 | −2 | 4 | −13 | 42 | 10 | 9 | 13 | 17 | 18 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 463 | 463 | 518 | 519 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 | 755 |
| Reserves | 3,585 | 3,998 | 4,626 | 3,543 | 5,846 | 5,906 | 5,365 | 5,423 | 6,487 | 6,908 | 8,162 | 9,141 | 9,723 |
| Borrowings | 1,784 | 1,513 | 2,217 | 1,962 | 2,010 | 1,594 | 1,531 | 1,255 | 926 | 1,155 | 2,475 | 3,473 | 3,164 |
| Other Liabilities | 1,760 | 1,257 | 2,227 | 2,455 | 2,875 | 2,781 | 3,216 | 4,082 | 3,921 | 4,153 | 1,985 | 2,465 | 2,772 |
| Total Liabilities | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,833 | 16,415 |
| Fixed Assets | 4,218 | 3,642 | 5,419 | 4,992 | 8,477 | 8,802 | 8,799 | 9,416 | 9,426 | 9,874 | 10,424 | 12,230 | 12,373 |
| CWIP | 228 | 226 | 268 | 226 | 450 | 204 | 165 | 193 | 228 | 542 | 407 | 434 | 495 |
| Investments | 1,464 | 1,452 | 1,878 | 1,732 | 270 | 175 | 186 | 104 | 210 | 230 | 169 | 243 | 254 |
| Other Assets | 1,682 | 1,913 | 2,023 | 1,529 | 2,290 | 1,856 | 1,716 | 1,803 | 2,225 | 2,326 | 2,378 | 2,926 | 3,292 |
| Total Assets | 7,592 | 7,232 | 9,588 | 8,479 | 11,486 | 11,036 | 10,866 | 11,516 | 12,089 | 12,971 | 13,377 | 15,833 | 16,415 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 24 | 195 | 966 | 493 | −179 | 172 | 485 | 865 | 822 | 1,100 | 1,424 | 1,601 |
| Investing | 213 | 122 | −1,001 | −333 | −3,279 | 63 | −131 | −501 | −372 | −889 | −780 | −1,537 |
| Financing | −304 | −354 | 259 | −672 | 4,257 | −862 | −143 | −517 | −471 | −86 | −714 | 164 |
| Net Cash Flow | −66 | −37 | 225 | −513 | 799 | −627 | 212 | −153 | −21 | 125 | −70 | 228 |
| Free Cash Flow | −181 | −162 | 689 | 437 | −261 | 35 | 274 | 750 | 367 | 172 | 591 | 673 |
| CFO/EBITDA | 131 | 354 | 304 | 187 | 30 | 84 | 108 | 101 | 100 | 104 | 97 | 90 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 38 | 39 | 38 | 38 | 44 | 36 | 41 | 33 | 34 | 33 | 37 | 42 |
| Inventory Days | 25 | 23 | 23 | 24 | 22 | 30 | 29 | 33 | 31 | 24 | 23 | 24 |
| Days Payable | 207 | 218 | 215 | 279 | 296 | 226 | 205 | 178 | 179 | 164 | 161 | 165 |
| Cash Conversion Cycle | −144 | −156 | −155 | −217 | −230 | −161 | −135 | −112 | −115 | −107 | −101 | −99 |
| Working Capital Days | −71 | −69 | −87 | −113 | −234 | −150 | −56 | −35 | −22 | −124 | −30 | −34 |
| ROCE % | 0% | 3% | 11% | 3% | 6% | 4% | 2% | 10% | 10% | 10% | 12% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fortis Healthcare insights
64 extracted metrics across FY13–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Concall · Sep 2026Transcript Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 5 Nov 2026
- 6 Aug 2026
- 13 Feb 2026
- 9 Sep 2026
- 5 Jan 2026
- 1 Sep 2025
- 30 Sep 2024
- 3 Apr 2024
- General announcements 6 Nov 2026
- General announcements 5 Nov 2026
Frequently Asked Questions about Fortis Healthcare
What does Fortis Healthcare Ltd do?
Where is Fortis Healthcare Ltd (FORTIS) listed?
Which sector does Fortis Healthcare Ltd belong to?
What is the market capitalisation of Fortis Healthcare Ltd?
What is the PE ratio of Fortis Healthcare Ltd?
What is the 52-week high and low of Fortis Healthcare Ltd?
Does Fortis Healthcare Ltd pay dividends?
What is the Return on Equity (ROE) of Fortis Healthcare Ltd?
Company Information
FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. Company controls its diagnostics business through its 57% owned subsidiary SRL Limited. It is amongst the largest private diagnostics chains. It has a presence in over 600 cities and towns, with an established strength of 415 laboratories, 8,200 direct clients and 1,400 Collection Centers.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FORTIS.md for Fortis Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.